Study design and patients’ baseline characteristics
The study was conducted as a sub-study of the Argentina Stop Trial (AST) registered in the National Registry of Health Research (RENIS: ISO02688) (Twenty-three patients (50%) were females and the Sokal score was low in 22 patients (47.8%). Patients were treated with imatinib (n = 37), dasatinib (n = 4) or nilotinib (n = 5) with branded (n = 35) or generic (n = 11) TKIs. Median duration of treatment was 128 months (range 52 - 244 months) and median duration of DMR (detectable BCR-ABL1IS ≤ 0.01%, or undetectable BCR-ABL1 with 10,000 or more ABL1 transcripts, i.e. at least MR4.0 or better) was 70 months (range 30 - 147 months).